Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Guilford Pharmaceuticals (NasdaqNM:GLFD)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options
Recent Events
Aug 22Price hit new 52-week low ($11.72)
Aug  6Conference call: Guilford Pharmaceuticals Earnings (Q2 2001)
Aug  6Earnings Announcement
Location
6611 Tributary Street
Baltimore, MD 21224
Phone: (410) 631-6300
Fax: (410) 631-6338
Email: webmaster@guilfordpharm.com
Employees (last reported count): 254
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 22%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · 10 insider sells; 86.0K shares
  (1.3% of insider shares)
·Institutional: 56% (71% of float)
(180 institutions)
·Net Inst. Buying: 2.23M shares (+11.88%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Guilford Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of novel products in two principal areas, targeted and controlled drug delivery systems using proprietary biodegradable polymers for the treatment of cancer and other diseases, and therapeutic and diagnostic products for neurological diseases and conditions. The Company's first product in its drug delivery business is GLIADEL Wafer, a novel treatment for glioblastoma multiforme. The Company is also engaged in the research and development of small molecules that regenerate damaged nerves or protect nerves from damage for potential treatment of a range of neurodegenerative diseases and conditions, such as Parkinson's disease, Alzheimer's disease, stroke, Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis, spinal cord injury and peripheral neuropathies.
More from Market Guide: Expanded Business Description

Financial Summary
GLFD is a biopharmaceutical company engaged in the development and commercialization of products in two principal areas: targeted and controlled drug delivery systems and therapeutic and diagnostic products. For the six months ended 6/30/01, revenues fell 7% to $7.9 million. Net loss before accounting change rose 95% to $32.7 million. Revenues reflect the absence of contract sales. Higher loss also reflects increased distribution expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

Craig Smith, M.D., 54
Pres, CEO and Chairman
$660K
David Wright
Exec. VP, Commercial Operations
--  
Andrew Jordan, 52
Sr. VP, Treasurer and CFO
302K
Thomas Seoh, 42
Sr. VP, Gen. Counsel, Sec.
296K
John Brennan, 57
Sr. VP- Technical Operations and Gen. Mang.- Drug Delivery Bus.
324K
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GLFDAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Aug-2001
$11.72 
Recent Price$12.05 
52-Week High
on 29-June-2001
$35.99 
Beta0.65 
Daily Volume (3-month avg)467.0K
Daily Volume (10-day avg)331.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-50.9%
52-Week Change
relative to S&P500
-34.2%
Share-Related Items
Market Capitalization$358.0M
Shares Outstanding29.7M
Float23.2M
Dividends & Splits
Annual Dividendnone 
Last Split: 3 for 2 on 13-Nov-1996
Per-Share Data
Book Value (mrq)$6.23 
Earnings (ttm)-$2.02 
Earnings (mrq)-$0.67 
Sales (ttm)$0.81 
Cash (mrq)$5.45 
Valuation Ratios
Price/Book (mrq)1.93 
Price/EarningsN/A 
Price/Sales (ttm)14.93 
Income Statements
Sales (ttm)$20.4M
EBITDA (ttm)-$52.5M
Income available to common (ttm)-$51.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-32.66%
Return on Equity (ttm)-36.92%
Financial Strength
Current Ratio (mrq)10.29 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$161.8M
Short Interest
As of 8-Aug-2001
Shares Short882.0K
Percent of Float3.8%
Shares Short
(Prior Month)
1.16M
Short Ratio1.15 
Daily Volume766.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.